Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APRIL: Abatacept in RA-ILD
NCT03084419Phase 2Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jun 2018
- Primary completion
- Mar 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in rheumatoid arthritis-associated interstitial lung disease (RA-ILD), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Forced Vital Capacity at 24 weeks. Status: unknown.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis-associated interstitial lung disease (RA-ILD)
Beyond the preview
Go deeper on NCT03084419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03084419.